Paper Details

  1. Home
  2. Paper Details

Methotrexate for induction of remission in refractory Crohn's disease.

Author: AlfadhliA A, FeaganB G, McDonaldJ W

ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

While corticosteroids are effective in treating Crohn’s disease initially, about 20% of patients experience a relapse when they stop taking steroids and become dependent on them. Since corticosteroids also have significant side effects, new treatments are needed. Methotrexate, a medication used for rheumatoid arthritis, has been investigated as a treatment for Crohn’s disease that doesn’t respond to other treatments. While it has become an alternative to other medications, its effectiveness needs further review.
Paper Details　
Original Abstract of the Article :
Although corticosteroids are effective for induction of remission of Crohn's disease, approximately 20% of patients who respond relapse when steroids are withdrawn and become steroid dependent (Binder 1985). Furthermore, corticosteroids exhibit significant adverse effects. The success of methotrexat...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/14651858.CD003459

データ提供：米国国立医学図書館（NLM）

Methotrexate for Induction of Remission in Refractory Crohn's Disease

Crohn's disease is a challenging condition, like a stubborn camel refusing to budge. This study investigates the effectiveness of methotrexate for inducing remission in patients with refractory Crohn's disease, a condition where conventional treatments have failed.

The study examines the use of methotrexate as an alternative to azathioprine/6MP therapy for refractory Crohn's disease. The study highlights the need for more comprehensive research to fully understand the effectiveness of methotrexate in this context.

A New Oasis for Refractory Crohn's?

This study explores the potential of methotrexate as a treatment option for refractory Crohn's disease. While the evidence is promising, the study suggests that more research is needed to confirm its efficacy and safety in this context. This is like finding a new oasis in the desert of Crohn's disease, but further exploration is required to ensure its reliability and benefits.

A Promising Path for Refractory Crohn's

The study provides a promising path for patients with refractory Crohn's disease. Methotrexate, like a skilled camel driver, might offer a new way to navigate the challenges of this debilitating condition. This research underscores the importance of continued exploration and development of new treatment options for refractory Crohn's disease.

Dr. Camel's Conclusion

This study provides a valuable glimpse into the ongoing quest for effective treatments for refractory Crohn's disease. Methotrexate shows potential as an alternative therapy, but further research is needed to fully understand its efficacy and safety. This exploration is like searching for a reliable oasis in the vast and challenging desert of Crohn's disease, offering hope for a more comfortable journey for those affected.

Date :
  1. Date Completed 2003-03-27
  2. Date Revised 2018-11-30
Further Info :

Pubmed ID

12535475

DOI: Digital Object Identifier

10.1002/14651858.CD003459

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.